Tackling Three Key Issues In China’s Health Reform
This article was originally published in PharmAsia News
Han Qi-de, vice chairman of the Standing Committee of the National People's Congress and President of Peking University Health Science Center, believes that three key problems exist in China's health care reform: health care availability, fairness and cost. Addressing the issues means establishing basic health care organizations, closing the gap between urban and rural areas, and offering medical care at affordable prices, respectively. There is a need to concurrently reform pharmaceutical production and distribution systems, as well as adopt practical measures to cut drug costs. Strict new drug approval processes, modern logistics in distribution, transparent medical income records in hospitals and a good legal system are some crucial factors toward achieving the objectives of the health reform. (Click here for more - Chinese Language)
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.